The potential of immunomodulatory drugs in the treatment of solid tumors

Future Oncology

Volumn 6, Issue 9, 2010, Pages 1479-1484

  Dalgleish, Angus ^a   Galustian, Christine ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

breast cancer; colorectal cancer; hematological malignancy; IMiDs ; immunomodulatory drug; lenalidomide; multiple myeloma; myelodysplastic syndrome; pancreatic cancer; pomalidomide; prostate cancer

Indexed keywords

CANCER VACCINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; LENALIDOMIDE; PNEUMOCOCCUS VACCINE; POMALIDOMIDE; PROVENGE; RITUXIMAB; SORAFENIB; SUNITINIB; VITAMIN D;

5Q- SYNDROME; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CHROMOSOME 5Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; COLORECTAL TUMOR; DRUG POTENTIATION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; NEOPLASMS; THALIDOMIDE;

EID: 77957958698     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.105     Document Type: Review

References (50)

1. Aragon-Ching JB, Li H, Gardner ER, Figg WD: Thalidomide analogues as anticancer drugs. Recent Pat. Anticancer Drug Discov. 2, 167-174 (2007).
2. Melchert M, List A: The thalidomide saga. Int. J. Biochem. Cell Biol. 39, 1489-1499 (2007).
3. Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314-322 (2004).
4. Richardson PG, Blood E, Mitsiades CS et al.: A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108, 3458-3464 (2006).
5. Richardson P, Jagannath S, Hussein M et al.: Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114, 772-778 (2009).
6. Weber DM, Chen C, Niesvizky R et al.: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133-2142 (2007
7. Dimopoulos M, Spencer A, Attal M et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123-2132 (2007)
8. Galustian C, Dalgleish A: Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin. Pharmacother. 10, 125-133 (2009).
9. Van Etten RA, Shannon KM: Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6, 547-552 (2004).
10. List A, Dewald G, Bennett J et al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456-1465 (2006).
11. Ortega J, List A: Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Curr. Opin. Oncol. 19, 656-659 (2007).
12. Sokol L, List AF: Immunomodulatory therapy for myelodysplastic syndromes. Int. J. Hematol. 86, 301-305 (2007).
13. Ades L, Boehrer S, Prebet T et al.: Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a Phase 2 study. Blood 113, 3947-3952 (2009).
14. Ferrajoli A, Lee BN, Schlette EJ et al.: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111, 5291-5297 (2008).
15. Ramsay AG, Johnson AJ, Lee AM et al.: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118, 2427-2437 (2008).
16. James DF, Betty MR, Mosadeghi R, Kipps TJ: Lenalidomide abrogates the protective influence of nurse-like cells on primary chronic lymphocytic leukemia cells in vitro. Blood 110, A916-A917 (2007).
17. Wildes TM, Bartlett NL: Drug development for recurrent and refractory classical Hodgkin lymphoma. Leuk. Lymphoma 50, 529-540 (2009).
18. Witzig TE, Wiernik PH, Moore T et al.: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J. Clin. Oncol. 27, 5404-5409 (2009).
19. Habermann TM, Lossos IS, Justice G et al.: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 145, 344-349 (2009).
20. Lapalombella R, Yu B, Triantafillou G et al.: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 112, 5180-5189 (2008).
21. Lapalombella R, Gowda A, Joshi T et al.: The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br. J. Haematol. 144, 848-855 (2009).
22. Awan FT, Lapalombella R, Trotta R et al.: CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115, 1204-1213 (2010).
23. Bartlett JB, Michael A, Clarke IA et al.: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 90, 955-961 (2004).
24. Dredge K, Marriott JB, Todryk SM et al.: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168, 4914-4919 (2002).
25. Rajkumar SV, Jacobus S, Callander N et al.: Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome wi. J. Clin. Oncol. 26(Suppl.), Abstract 8504 (2008).
26. Liu W, Nizar S, Dalgleish A: Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Med. Oncol. 27, 430-433 (2010).
27. Galustian C, Meyer B, Labarthe MC et al.: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 58, 1033-1045 (2009).
28. Henry JY, Lu L, Adams M et al.: Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Presented at: 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 17-21 April 2010.
29. Ning YM, Gulley JL, Arlen PM et al.: Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 2070-2076 (2010).
30. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L: A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother. Pharmacol. 65, 811-815 (2010).
31. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG: A Phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J. Clin. Oncol. 27(Suppl.), Abstr. 5156 (2009).
32. Nabhan C, Tolzien K, Kelby K, Lestingi TM: Lenalidomide (Revlimid®) has single agent activity in chemotherapy-naïve castration-resistant prostate cancer (CRPC). Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010.
33. Sinibaldi VJ, Carducci MA, Moore-Cooper S et al.: A randomized double blind Phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT). J. Clin. Oncol. 27(Suppl.), Abstr. 5130 (2009).
34. Brosseau C, Colston K, Dalgleish AG, Galustian C: The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231. Presented at: 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 17-21 April 2010.
35. Liu WM, Fowler DW, Smith P, Dalgleish AG: Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J Cancer 102, 115-123 (2010).
36. Blansfield JA, Caragacianu D, Alexander HR III et al.: Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin. Cancer Res. 14, 270-280 (2008).
37. Dalgleish AG, O'Byrne K: Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat. Res. 130, 1-38 (2006).
38. + T cells. Clin. Exp. Immunol. 130, 75-84 (2002).
39. Noonan KA, Ferguson A, Emerling A et al.: Lenalidomide augments immune responses to prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines. ASH Annual Meeting Abstracts 114, 1864 (2009).
40. Schey SA, Fields P, Bartlett JB et al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22, 3269-3276 (2004).
41. Kran AM, Sorensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D: Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 20, 627-630 (2006).
42. Cadogan M, Austen B, Heeney JL, Dalgleish AG: HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. AIDS Res. Hum. Retroviruses 24, 845-855 (2008).
43. Cadogan M, Dalgleish AG: Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin. Med. 8, 267-271 (2008).
44. Cadogan M, Dalgleish AG: HIV immunopathogenesis and strategies for intervention. Lancet Infect. Dis. 8, 675-684 (2008).
45. Cadogan M, Dalgleish AG: HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies. Adv. Cancer Res. 101, 349-395 (2008).
46. Maraveyas A, Baban B, Kennard D et al.: Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann. Oncol. 10, 817-824 (1999).
47. Dlugovitzky D, Bottasso O, Dominino JC et al.: Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir. Med. 93, 557-562 (1999).
48. O'Brien ME, Saini A, Smith IE et al.: A randomized Phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br. J Cancer 83, 853-857 (2000).
49. Assersohn L, Souberbielle BE, O'Brien ME et al.: A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 14, 23-27 (2002).
50. Mwinga A, Nunn A, Ngwira B et al.: Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 360, 1050-1055 (2002)